Andrew Fedanov
Overview
Explore the profile of Andrew Fedanov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Branella G, Lee J, Okalova J, Parwani K, Alexander J, Arthuzo R, et al.
Front Immunol
. 2023 Nov;
14:1294555.
PMID: 38022523
The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell...
2.
Yu T, Jhita N, Shankles P, Fedanov A, Kramer N, Raikar S, et al.
Lab Chip
. 2023 Oct;
23(22):4804-4820.
PMID: 37830228
Genetic reprogramming of immune cells to recognize and target tumor cells offers a possibility of long-term cure. Cell therapies, however, lack simple and affordable manufacturing workflows, especially to genetically edit...
3.
Lee J, Jonus H, Sadanand A, Branella G, Maximov V, Suttapitugsakul S, et al.
Cell Rep Med
. 2023 Jun;
4(6):101091.
PMID: 37343516
GD2-targeting immunotherapies have improved survival in children with neuroblastoma, yet on-target, off-tumor toxicities can occur and a subset of patients cease to respond. The majority of neuroblastoma patients who receive...
4.
Ronald Funk C, Wang S, Chen K, Waller A, Sharma A, Edgar C, et al.
Blood
. 2022 Jan;
139(4):523-537.
PMID: 35084470
Current limitations in using chimeric antigen receptor T(CART) cells to treat patients with hematological cancers include limited expansion and persistence in vivo that contribute to cancer relapse. Patients with chronic...
5.
Knight K, Coyle C, Radford C, Parker E, Fedanov A, Shields J, et al.
Blood Adv
. 2021 Sep;
5(17):3333-3343.
PMID: 34477814
Orthologous proteins contain sequence disparity guided by natural selection. In certain cases, species-specific protein functionality predicts pharmacological enhancement, such as greater specific activity or stability. However, immunological barriers generally preclude...
6.
Zoine J, Prince C, Story J, Branella G, Lytle A, Fedanov A, et al.
Gene Ther
. 2021 Aug;
29(5):1-12.
PMID: 34385604
While targeting CD19+ hematologic malignancies with CAR T cell therapy using single chain variable fragments (scFv) has been highly successful, novel strategies for applying CAR T cell therapy with other...
7.
Hamilton J, Lee M, Hunter R, Ank R, Story J, Talekar G, et al.
Aging Cell
. 2021 Jan;
20(2):e13309.
PMID: 33480151
Aging-associated declines in innate and adaptive immune responses are well documented and pose a risk for the growing aging population, which is predicted to comprise greater than 40 percent of...
8.
Fleischer L, Becker S, Ryan R, Fedanov A, Doering C, Spencer H
Mol Ther Oncolytics
. 2020 Jul;
18:149-160.
PMID: 32671190
Chimeric antigen receptor (CAR)-modified T cells have demonstrated efficacy against B cell leukemias/lymphomas. However, redirecting CAR T cells to malignant T cells is more challenging due to product-specific - and...
9.
Takushi S, Paik N, Fedanov A, Prince C, Doering C, Spencer H, et al.
Hum Gene Ther
. 2020 Apr;
31(11-12):626-638.
PMID: 32253931
Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) is a rare disease caused by mutations to the gene and the subsequent absence or decreased activity of the Munc13-4 protein. Munc13-4 is essential...
10.
Smith I, dAquino A, Coyle C, Fedanov A, Parker E, Denning G, et al.
J Thromb Haemost
. 2019 Aug;
18(1):57-69.
PMID: 31454152
Background: Coagulation factor VIII represents one of the oldest protein-based therapeutics, serving as an effective hemophilia A treatment for half a century. Optimal treatment consists of repeated intravenous infusions of...